Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). [electronic resource]
Producer: 20091207Description: 116-24 p. digitalISSN:- 1468-1293
- Adult
- Aged
- Benzoates -- pharmacokinetics
- Diketopiperazines
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- HIV Infections -- drug therapy
- HIV Protease Inhibitors -- pharmacokinetics
- HIV-1 -- immunology
- Humans
- Lopinavir
- Male
- Middle Aged
- Piperazines -- pharmacokinetics
- Pyrimidinones -- pharmacokinetics
- RNA, Viral -- immunology
- Receptors, CCR5 -- therapeutic use
- Ritonavir -- pharmacokinetics
- Spiro Compounds -- pharmacokinetics
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.